Evidence map›Paper›PMID 32627041›Full record

ArticleOncology reports2020

High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer.

Ryotaro Ohkuma, Erica Yada, Shumpei Ishikawa, Daisuke Komura, Yutaro Kubota, Kazuyuki Hamada, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Polymeric immunoglobulin receptor (pIgR) in cancer.Journal of cancer research and clinical oncology · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Ryotaro OhkumaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Erica YadaKanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241‑8515, Japan.
Shumpei IshikawaDepartment of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑0033, Japan.
Daisuke KomuraDepartment of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑0033, Japan.
Yutaro KubotaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Kazuyuki HamadaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Atsushi HoriikeDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Tomoyuki IshiguroDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Yuya HirasawaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Hirotsugu AriizumiDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Midori ShidaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Makoto WatanabeDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Rie OnoueDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Kiyohiro AndoDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Junji TsurutaniDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Kiyoshi YoshimuraDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Tetsuro SasadaKanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241‑8515, Japan.
Takeshi AokiDepartment of Surgery, Division of General and Gastroenterological Surgery, Showa University, Tokyo 142‑8555, Japan.
Masahiko MurakamiDepartment of Surgery, Division of General and Gastroenterological Surgery, Showa University, Tokyo 142‑8555, Japan.
Tomoko NoroseDepartment of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Nobuyuki OhikeDepartment of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Masafumi TakimotoDepartment of Pathology and Laboratory Medicine, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Shinichi KobayashiClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Takuya TsunodaDepartment of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo 142‑8555, Japan.
Satoshi WadaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo 157‑8577, Japan.
Showa University · JPKanagawa Prefectural Hospital Organization · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer has extremely poor prognosis, warranting the discovery of novel therapeutic and prognostic markers. The expression of polymeric immunoglobulin receptor (pIgR), a key component of the mucosal immune system, is increased in several cancers. However, its clinical relevance in pancreatic cancer remains unclear. In the present study, the prognostic value of pIgR in pancreatic cancer patients after surgical resection was assessed and it was determined that the expression of pIgR was correlated with poor prognosis. Ten pancreatic cancer patient‑derived xenograft (PDX) lines were established, followed by next‑generation sequencing of tumor tissues from these lines after standard chemotherapy. Immunohistochemical analysis of chemoresistance‑related molecules using 77 pancreatic cancer tissues was also performed. The expression of pIgR mRNA in the PDX group treated with anticancer drugs was higher than in the untreated group. High pIgR expression in tissue specimens from 77 pancreatic cancer patients was significantly associated with poor prognosis and was revealed to be an independent prognostic factor, predicting poor outcomes. High pIgR mRNA and protein levels were independent prognostic factors, indicating that pIgR could be a novel predictor for poor prognosis of pancreatic cancer patients.

Indexed as

Drug Resistance, NeoplasmAgedAnimalsAntineoplastic AgentsBiomarkers, TumorCell Line, TumorFemaleGene Expression ProfilingHigh-Throughput Nucleotide SequencingHumansMaleMiceMiddle AgedNeoplasm TransplantationPancreatic NeoplasmsPrognosisAntineoplastic AgentsBiomarkers, TumorReceptors, Polymeric Immunoglobulinbiomarkerchemoresistancepancreatic cancerpatient-derived xenograftpolymeric immunoglobulin receptorpoor prognosis

Identifiers

PMID32627041
PMCPMC7251687
OpenAlexW3024312082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.